NTHI (NeOnc Technologies Holdings) Return-on-Tangible-Equity: 0.00% (As of Mar. 2026)


NTHI NeOnc Technologies Holdings Inc NTHI
7 GF Score
Price $4.35
! 1 Warning Sign
View Full Analysis

What is NeOnc Technologies Holdings Return-on-Tangible-Equity?

NeOnc Technologies Holdings NTHI -2.58% 7 Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus rates NTHI with a GF Score™ of 7/100. The stock has 1 warning sign investors should review. Among 1,195 Biotechnology companies, NeOnc Technologies Holdings ranks worse than 83681.92% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. NeOnc Technologies Holdings's annualized net income for the quarter that ended in Mar. 2026 was $-35.28 Mil. NeOnc Technologies Holdings's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $-15.86 Mil. Therefore, NeOnc Technologies Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.

The historical rank and industry rank for NeOnc Technologies Holdings's Return-on-Tangible-Equity or its related term are showing as below:

NTHI's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.21
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

NeOnc Technologies Holdings  (NAS:NTHI) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


NeOnc Technologies Holdings Return-on-Tangible-Equity Related Terms


NeOnc Technologies Holdings Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for NeOnc Technologies Holdings's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeOnc Technologies Holdings Return-on-Tangible-Equity Chart

NeOnc Technologies Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Equity
0.00 0.00 0.00 0.00 0.00

NeOnc Technologies Holdings Quarterly Data
Dec21 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NTHI vs GUTS, PEPG, ENGN: Return-on-Tangible-Equity Comparison

For the Biotechnology subindustry, NeOnc Technologies Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeOnc Technologies Holdings Return-on-Tangible-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeOnc Technologies Holdings's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where NeOnc Technologies Holdings's Return-on-Tangible-Equity falls into.


NTHI
7GF Score
NeOnc Technologies Holdings Inc NTHI
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeOnc Technologies Holdings Return-on-Tangible-Equity Calculation

NeOnc Technologies Holdings's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-62.146/( (-5.505+-18.008 )/ 2 )
=-62.146/-11.7565
=N/A %

NeOnc Technologies Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-35.28/( (-18.008+-13.719)/ 2 )
=-35.28/-15.8635
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
NeOnc Technologies Holdings (NTHI) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NeOnc Technologies Holdings and its competitors. According to the industry distribution chart, NeOnc Technologies Holdings ranks #999999 out of 1195 companies in the Biotechnology industry.
Is NeOnc Technologies Holdings' Return-on-Tangible-Equity too high?
NeOnc Technologies Holdings' current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, NeOnc Technologies Holdings ranks #999999 out of 1195 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NeOnc Technologies Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does NeOnc Technologies Holdings' Return-on-Tangible-Equity compare to GUTS and PEPG?
According to the Biotechnology industry distribution chart, NeOnc Technologies Holdings ranks #999999 out of 1195 companies for Return-on-Tangible-Equity. This places NeOnc Technologies Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NeOnc Technologies Holdings and its competitors. NeOnc Technologies Holdings's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeOnc Technologies Holdings stock overvalued right now?
NeOnc Technologies Holdings (NTHI) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. NeOnc Technologies Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For NeOnc Technologies Holdings (NTHI), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeOnc Technologies Holdings Business Description

Address 23975 Park Sorrento, Suite 205, Calabasas, CA, USA, 91302
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
7GF Score

Get the complete analysis for NTHI

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.35
Price